Attached files

file filename
EX-4.2 - EXHIBIT 4.2 - ENZON PHARMACEUTICALS, INC.v434165_ex4-2.htm
EX-32.1 - EXHIBIT 32.1 - ENZON PHARMACEUTICALS, INC.v434165_ex32-1.htm
EX-31.2 - EXHIBIT 31.2 - ENZON PHARMACEUTICALS, INC.v434165_ex31-2.htm
EX-21.1 - EXHIBIT 21.1 - ENZON PHARMACEUTICALS, INC.v434165_ex21-1.htm
EX-32.2 - EXHIBIT 32.2 - ENZON PHARMACEUTICALS, INC.v434165_ex32-2.htm
EX-31.1 - EXHIBIT 31.1 - ENZON PHARMACEUTICALS, INC.v434165_ex31-1.htm
EX-10.29 - EXHIBIT 10.29 - ENZON PHARMACEUTICALS, INC.v434165_ex10-29.htm
EX-10.28 - EXHIBIT 10.28 - ENZON PHARMACEUTICALS, INC.v434165_ex10-28.htm
10-K - FORM 10-K - ENZON PHARMACEUTICALS, INC.v434165_10k.htm
EX-10.27 - EXHIBIT 10.27 - ENZON PHARMACEUTICALS, INC.v434165_ex10-27.htm

 

EXHIBIT 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the Registration Statements of Enzon Pharmaceuticals, Inc. and Subsidiaries on Form S-3 (No. 333-137723) and Form S-8 (Nos. 333-174099, 333-140282,333-134453, 333-132467, 333-121468, 333-101898, 333-64110, and 333-18051) of our report dated March 21, 2016, on our audits of the consolidated financial statements as of December 31, 2015 and 2014 and for each of the years then ended, which report is included in this Annual Report on Form 10-K to be filed on or about March 21, 2016.

 

/s/ EISNERAMPER LLP

 

Iselin, New Jersey

March 21, 2016